2-苯氧基甲基-喹啉 | 107813-49-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-苯氧基甲基-喹啉
• 英文名称: 2-(phenoxymethyl)quinoline
• 英文别名: 2-Phenoxymethyl-quinoline
• CAS: 107813-49-0
• 化学式: C₁₆H₁₃NO
• 分子量: 235.285
• InChiKey: MARJKKBMAPXHAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-苯氧基甲基-喹啉 在 水 、 氢碘酸 作用下， 生成 2-甲基喹啉
  参考文献：
  名称：

  Okuda, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1951, vol. 71, p. 1275

  摘要：

  DOI：
• 作为产物：
  描述：

  苯氧基丙酮 在 氢氧化钾 、 铜 作用下， 生成 2-苯氧基甲基-喹啉
  参考文献：
  名称：

  Okuda, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1951, vol. 71, p. 1275

  摘要：

  DOI：

文献信息

• Synthesis of 2-Substituted Quinolines <i>via</i> Rhodium(III)-Catalyzed C-H Activation of Imidamides and Coupling with Cyclopropanols
  作者：Xukai Zhou、Zisong Qi、Songjie Yu、Lingheng Kong、Yang Li、Wan-Fa Tian、Xingwei Li

  DOI：10.1002/adsc.201601278

  日期：2017.5.17

  An efficient synthesis of 2-substituted quinolines from readily available cyclopropanols and imidamides has been developed, where the cyclopropanol acts as a C3 synthon. With the assistance of a bifunctional imidamide directing group, the reaction occurred via sequential C–H/C–C cleavage and C–C/C–N bond formation.

  已经开发了从容易获得的环丙醇和酰亚胺酰胺有效合成2-取代的喹啉的方法，其中环丙醇充当C 3合成子。在双官能的酰亚胺酰胺导向基团的协助下，反应通过顺序的C–H / C–C裂解和C–C / C–N键形成而发生。
• Aryl and heteroaryl ethers as agents for the treatment of hypersensitive
  申请人：USV Pharmaceutical Corp.

  公开号：US04631287A1

  公开（公告）日：1986-12-23

  The present invention is concerned with the therapeutic composition comprising as an active ingredient a compound of the formula: (R.sub.1)(R.sub.2)Ar--Z--M--Ar.sub.1 (R.sub.3)(R.sub.4) I and salts thereof; wherein Ar and Ar.sub.1 are independently phenyl, naphthyl or a nitrogen, oxygen, or sulfur heterocyclic ring; Z is an alkylene chain containing from 1 to 5 carbon atoms in the principal chain and up to a total of 10 carbon atoms; M is oxygen, sulfur, or NR.sub.5 ; R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently H, lower alkyl, lower alkoxy, hydroxy, halo, trihalomethyl, hydroxy lower alkyl, carboxy, formyl, aryl, aryloxy, benzyloxy, lower alkanoyl, carboxy lower alkoxy, nitro, amino, lower alkylamino, dilower alkylamino, cyano, lower alkanoyloxy, carbamoyl, lower alkoxy-alkoxy, carbo-lower-alkoxy-alkoxy, or tetrahydropyranylmethyl; and R.sub.5 is hydrogen or lower alkyl.

  本发明涉及一种治疗组合物，其作为活性成分包含以下化合物或其盐：(R.sub.1)(R.sub.2)Ar--Z--M--Ar.sub.1 (R.sub.3)(R.sub.4)。其中，Ar和Ar.sub.1分别独立地为苯基、萘基或氮、氧或硫杂环；Z为主链中含有1至5个碳原子的烷基链，并且总共不超过10个碳原子；M为氧、硫或NR.sub.5；R.sub.1、R.sub.2、R.sub.3和R.sub.4各自独立地为H、低碳基、低烷氧基、羟基、卤素、三卤甲基、羟基低烷基、羧基、甲酰基、芳基、芳氧基、苄氧基、低烷酰基、羧基低烷氧基、硝基、氨基、低烷基氨基、二低烷基氨基、氰基、低烷酰氧基、氨甲酰基、低烷氧基-烷氧基、羧基-低烷氧基-烷氧基或四氢吡喃甲基；R.sub.5为氢或低碳基。
• Aryl and heteroaryl ethers as agents for the treatment of hypersensitive aliments
  申请人：USV PHARMACEUTICAL CORPORATION

  公开号：EP0200101A2

  公开（公告）日：1986-12-10

  The present invention is concerned with the therapeutic composition comprising as an active ingredient a compound of the formula: and salts thereof; wherein Ar and Ar, are independently phenyl, naphthyl or a nitrogen, oxygen, or sulfur heterocyclic ring; R,, R2 and R3 are independently H, lower alkyl, lower alkoxy, hydroxy, halo, trihalomethyl, hydroxy-lower alkyl, alkyl carboxy, carboxy, formyl, lower alkyl carbonyl, aryl, aryloxy, benzyloxy, lower alkylamino, diloweralkylamino, cyano, lower alkanoyloxy, carbamoyl, lower alkoxy-lower alkoxy, lower carbalkoxy-lower alkoxy, nitro, amino, tetrahydropyranylmethyl, tetrazole, tetrazole lower alkyl, formyl amino or lower alkanoylamino; R, is independently H, lower alkyl, lower alkoxy, hydroxy, halo, trihalomethyl, hydroxy-lower alkyl, alkyl carboxy, carboxy, formyl, lower alkyl carbonyl, aryl, aryloxy, benzyloxy, lower alkylamino, diloweralkylamino, cyano, lower alkanoyloxy, carbamoyl, lower alkoxy-lower alkoxy, lower carbalkoxy-lower alkoxy, nitro, amino, tetrahydropyranylmethyl, or tetrazole, or tetrazole lower alkyl or Rs; Rs is lower alkoxy, phenyl, OH, CO2R6cyclic or heterocyclic structures.

  本发明涉及治疗组合物，该组合物包含作为活性成分的式化合物： 及其盐类；其中 Ar和Ar，独立地是苯基、萘基或氮、氧或硫杂环； R、R2 和 R3 独立地为 H、低级烷基、低级烷氧基、羟基、卤代、三卤甲基、羟基-低级烷基、烷基羧基、羧基、甲酰基、低级烷基羰基、芳基、芳氧基、苄氧基、低级烷基氨基、稀低级烷基氨基、氰基、烷基羰基、芳基羰基、芳氧基、苄氧基、低级烷基酰胺、稀低级烷基酰胺、低级烷基羰基下烷基羰基、芳基、芳氧基、苄氧基、下烷基氨基、稀烷基氨基、氰基、下烷酰氧基、氨基甲酰基、下烷氧基-下烷氧基、下碳烷氧基-下烷氧基、硝基、氨基、四氢吡喃甲基、四唑、四唑下烷基、甲酰氨基或下烷基氨基； R，独立地为 H、低级烷基、低级烷氧基、羟基、卤代、三卤甲基、羟基-低级烷基、烷基羧基、羧基、甲酰基、低级烷基羰基、芳基、芳氧基、苄氧基、低级烷基氨基低级烷基羰基、芳基、芳氧基、苄氧基、低级烷基氨基、稀低级烷基氨基、氰基、低级烷酰氧基、氨基甲酰基、低级烷氧基-低级烷氧基、低级碳烷氧基-低级烷氧基、硝基、氨基、四氢吡喃甲基、或四唑、或四唑低级烷基或 Rs； Rs 是低级烷氧基、苯基、OH、CO2R6 环结构或杂环结构。
• Rare-Earth Y(OTf)₃ Catalyzed Coupling Reaction of Ethers with Azaarenes
  作者：Yue-Hua Wu、Nai-Xing Wang、Tong Zhang、Lei-Yang Zhang、Xue-Wang Gao、Bao-Cai Xu、Yalan Xing、Jian-Yi Chi

  DOI：10.1021/acs.orglett.9b02763

  日期：2019.9.20

  Rare-earth catalysis has become a hot topic in the field of catalytic organic reaction. Chain ethers mostly have lower reactivity and lower boiling points which limited their reaction scope. Herein, we found a rare-earth Y(OTf)(3) can catalyze the coupling reaction of ethers especially chain ethers and thioethers with azaarenes. This protocol features simple operations, a broad substrate scope (31 examples), moderate to good yields (up to 85%), and atom economy.
• Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 1. Initial structure-activity relationships
  作者：Raymond D. Youssefyeh、Ernest Magnien、Thomas D. Y. Lee、Wan Kit Chan、Clara J. Lin、Robert A. Galemmo、William H. Johnson、Jenny Tan、Henry F. Campbell

  DOI：10.1021/jm00166a016

  日期：1990.4

  This series of reports describes the development of orally active, highly potent, specific antagonists of the peptidoleukotrienes containing a (2-quinolinylmethoxy)phenyl moiety. Described in this first report are the structure-activity relationships that led to a more than a 20-fold improvement of the potency and selectivity of the initial chemical lead (RG 5901). From this series of compounds, RG 7152 (16) was identified and selected for further evaluation in the clinic as an antiasthmatic agent. Compound 16 competitively inhibits [3H]LTD4 binding to membranes from guinea pig lung (Ki = 38 +/- 6 nM) and the spasmogenic activity of LTC4, LTD4, and LTE4 in parenchymal lung strips from guinea pigs. Unlike the original lead (RG 5901), compound 16 does not inhibit 5-lipoxygenase from guinea pig PMNs. Following oral administration to guinea pigs, 16 blocks LTD4-induced dermal permeability (ED50 = 6.9 mg/kg), LTD4-induced bronchoconstriction (ED50 = 1.1 mg/kg), antigen-induced bronchoconstriction (ED50 = 2.5 mg/kg), and anaphylactic-induced mortality (ED50 = 16 mg/kg). These studies on structure-activity relationships indicate that there is a requirement for an acidic function and the presence of the (2-quinolinylmethoxy)phenyl moiety in a specific geometric arrangement.